Understanding the Market | HIGHTIDE-B rose nearly 8% as losses narrowed by 42.96% year-on-year in the first half

HIGHTIDE-B rose nearly 8%, as of the time of writing, up 7.94%, priced at HKD 3.4, with a transaction volume of HKD 5.8183 million. In terms of news, HIGHTIDE-B released its interim results for the six months ending June 30, 2025, reporting other income of RMB 10.542 million, a year-on-year decrease of 69.96%; a loss attributable to shareholders of RMB 120 million, a year-on-year narrowing of 42.96%; and a basic loss per share of RMB 0.27. The announcement stated that the decrease in other income was mainly due to a reduction in government subsidies of approximately RMB 19.1 million. The company's core product HTD1801 is a globally innovative oral anti-inflammatory and metabolic regulator targeting the gut-liver system. Currently, HTD1801 is being developed globally for the treatment of CKM-related diseases, including type 2 diabetes (T2DM), metabolic-associated fatty liver disease (MASH), chronic kidney disease (CKD), obesity, primary sclerosing cholangitis (PSC), and severe hypertriglyceridemia (SHTG)